Frequency Therapeutics

General Information

We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Progenitor Cell Activation, or PCA, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. Further, these progenitor cells, which are closely related to stem cells, are already resident in the targeted location in the body and programmed to develop and differentiate into specific cell types within an organ.

Employees: 37
Founded: 2014
Contact Information
Address 19 Presidential Way, Woburn, MA 01801, US
Phone Number (866) 389-1970
Web Address
View Prospectus: Frequency Therapeutics
Financial Information
Market Cap $426.4mil
Revenues $0 mil (last 12 months)
Net Income $-23.3 mil (last 12 months)
IPO Profile
Symbol FREQ
Exchange NASDAQ
Shares (millions): 6.0
Price range $14.00 - $14.00
Est. $ Volume $84.0 mil
Manager / Joint Managers J.P. Morgan/ Goldman Sachs/ Cowen and Company
CO-Managers Mizuho Securities
Expected To Trade: 10/3/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change